FDA Approves Boston Scientific’s SYNERGY BP Stent For High Bleeding Risk Patients
The bioabsorbable polymer-coated, sirolimus-eluting stent is the first drug-eluting stent approved for this population.
You may also be interested in...
Boston Scientific’s management believes the ongoing recovery of procedure volumes and new technology will allow it to show revenue growth in the fourth quarter.
Results from two trials confirm patients at high risk of bleeding treated with Abbott’s Xience stent can be safely treated with short regimens of dual antiplatelet therapy.
The agency approved Medtronic's zotarolimus-eluting coronary stent for patients with a high bleeding risk who are treated with one month of dual-antiplatelet therapy.